Popular Articles

Chembio Awarded Three-Year $3MM NIH SBIR Phase II Grant To Complete DPP(R) Test For Human Leptospirosis
Chembio Diagnostic Systems, Inc. (a wholly-owned subsidiary of Chembio Diagnostics, Inc.) (OTCBB: CEMI) has been awarded a three-year $3 million Small Business Innovative Research (SBIR) Phase II grant from the United States National Institutes of Health (NIH) to fully develop, validate, and commercialize a rapid diagnostic test for leptospirosis for general use worldwide. The test will be developed utilizing Chembio"s patented Dual Path Platform (DPP®) technology together with proprietary reagents developed by Cornell University and the Oswaldo Cruz Foundation at the Brazilian Ministry of Health.

Taxing Fatty Foods Or Health Insurers Gains Traction
Lawmakers are considering two new taxes to help pay for a health care overhaul: a tax on fatty foods and taxing insurers on so-called Cadillac plans. Both proposals were scrutinized in news articles.
News of the day
Sotomayor Nomination Raises Questions About How Female Judges View Cases Differently
Following President Obama"s nomination of Judge Sonia Sotomayor to replace retiring Supreme Court Justice David Souter, the differences between how male and female judges see and rule on cases has come into question, the New York Times reports. Although retired Supreme Court Justice Sandra Day O"Connor, the first woman to serve on the Supreme Court, often said that a female judge would come to the same decision as a male judge, Justice Ruth Bader Ginsburg has said that her perspective on certain cases is different because of her gender.The Times cites two examples, one involving the strip search of a 13-year-old girl -- to which Ginsburg said that her male colleagues could not understand how the girl felt. The second example involves the issue of certain abortion procedures. When deciding about the constitutionality of a federal ban on so-called "partial-birth" abortions, Ginsburg took issue with Justice Anthony Kennedy"s majority opinion that women who undergo the procedure likely would experience attacks of conscience. She responded that Kennedy"s views reflected "ancient notions of women"s place in the family and under the Constitution -- ideas that have long since been discredited."The issue has come up again with Sotomayor"s nomination, specifically regarding her 2001 statement that she "would hope that a wise Latina woman with the richness of her experiences would more often than not reach a better conclusion than a white male who hasn"t lived that life." The perception that female judges inherently might view cases differently than male judges has raised some concerns even among some female judges who believe it might be true, according to the Times. Judge Judith Kaye, former chief judge of New York state, said that she avoided discussing the issue with others but then accepted the idea that female judges see things differently at times. "To defend the idea that women come out different on some cases, I just feel it," Kaye said, adding, "I feel it to the depths of my soul" because women"s experiences are "just different." Attorney Lawrence Robbins, however, said, "Any person in the real world should be highly reluctant to make these broad generalizations."The most recent study comparing male and female judges found that female judges were more likely to rule in favor of plaintiffs who claim sex discrimination at workplaces. The study also found no differences in cases involving disability law, environmental issues and capital punishment (Lewis, New York Times, 6/3).
Cardiovascular

Anti-Growth Factor Drugs Raise Hope And Concern For Treatment Of Children's Eye Diseases

A new class of antibody drugs may provide a powerful new tool for the treatment of eye diseases in children, but specialists need to be alert for the possibility of serious side effects, according to an editorial in the August Journal of AAPOS (American Association for Pediatric Ophthalmology and Strabismus), published by Elsevier. Dr. Robert L. Avery of Santa Barbara, Calif., discusses issues related to the use of antibodies against vascular endothelial growth factor (VEGF) in pediatric ophthalmology. The two anti-VEGF antibodies available so far - bevacizumab and ranibizumab - have been rapidly adopted for the treatment of age-related macular degeneration (AMD), the leading cause of vision loss in older adults. The antibodies work by blocking the development of new blood vessels (angiogenesis). Anti-VEGF antibodies were originally approved for use in cancer treatment, and there have been some safety concerns, including a possible increase in stroke risk. However, at the much smaller doses used in eye diseases, the two antibodies appear to be safe. However, in discussing the growing use of anti-VEGF antibodies in children, Dr. Avery sounds a cautious note. One study, also published in the August Journal of AAPOS, found that bevacizumab treatment in one eye of a child with eye disease also improved the condition in the other eye. This, along with other limited reports, suggests that the antibodies might leave the eye and enter the bloodstream, where they could potentially lead to side effects and complications. Side effects are a special concern in children, who might be at higher risk because of their smaller size. Used in premature infants with an eye disease called retinopathy of prematurity, anti-VEGF antibodies could have the potential for harm to still developing organs. These issues are particularly difficult because the anti-VEGF antibodies are not approved for use in children. Because of the urgent need for treatment of serious but relatively rare eye diseases in children, "off-label" use of drugs - for purposes other than those which the drugs are approved - is common in pediatric ophthalmology. A study is being performed to compare the two anti-VEGF antibodies in adults with AMD. Because ranibizumab stays in the body for a shorter time than bevacizumab, it might be a better choice for use in treating eye diseases. However, the upcoming study may not be large enough to detect small differences in side effects, and in any case the results may not be applicable to children. Meanwhile, Dr. Avery urges pediatric ophthalmologists using anti-VEGF antibodies to watch carefully for any possible side effects in their young patients. "Bevacizumab and ranibizumab have provided us with a great opportunity to improve the treatment of a variety of retinal diseases," he concludes. "Hopefully, the dramatic improvements in outcomes we have seen in adults will extend into pediatric diseases, but further study is clearly needed to assess the safety and efficacy of these drugs in this population." The articles appear in Journal of AAPOS, August 2009, published by Elsevier. Jayne Dawkins Elsevier


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):